Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus cetuximab versus cetuximab in HPV-negative recurrent or metastatic head and neck squamous cell carcinoma
2015-000515-41Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) and squamous cell carcinoma (SCC) comparing Palbociclib plus cetuximab with Cetuximab (2 arms). Primary endpoint: Overall survival. Started Jun 2015; status: completed.
02
Drugs
palbociclibcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on 2015-000515-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000515-41.